CytoDyn reports primary endpoint achieved in PRO 140 pivotal combination therapy trial
CytoDyn reports successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO 140 in combination with existing antiretroviral therapy in patients failing current HIV therapy. The trial data show a statistically significant reduction in HIV-1 RNA viral load. February 20, 2018